bluebird bio Inc (BLUE) : Clarius Group reduced its stake in bluebird bio Inc by 13.71% during the most recent quarter end. The investment management company now holds a total of 8,341 shares of bluebird bio Inc which is valued at $473,769 after selling 1,325 shares in bluebird bio Inc , the firm said in a disclosure report filed with the SEC on Aug 12, 2016.bluebird bio Inc makes up approximately 0.24% of Clarius Group’s portfolio.
Other Hedge Funds, Including , Portolan Capital Management reduced its stake in BLUE by selling 26,975 shares or 42.11% in the most recent quarter. The Hedge Fund company now holds 37,090 shares of BLUE which is valued at $2,106,712. bluebird bio Inc makes up approx 0.28% of Portolan Capital Management’s portfolio.Blackrock Fund Advisors boosted its stake in BLUE in the latest quarter, The investment management firm added 616,095 additional shares and now holds a total of 1,386,229 shares of bluebird bio Inc which is valued at $78,737,807. bluebird bio Inc makes up approx 0.02% of Blackrock Fund Advisors’s portfolio. Capital Fund Management S.a. added BLUE to its portfolio by purchasing 6,803 company shares during the most recent quarter which is valued at $381,784. bluebird bio Inc makes up approx 0.01% of Capital Fund Management S.a.’s portfolio.Alps Advisors Inc boosted its stake in BLUE in the latest quarter, The investment management firm added 10,368 additional shares and now holds a total of 51,898 shares of bluebird bio Inc which is valued at $2,912,516. bluebird bio Inc makes up approx 0.03% of Alps Advisors Inc’s portfolio. Nisa Investment Advisors sold out all of its stake in BLUE during the most recent quarter. The investment firm sold 3,300 shares of BLUE which is valued $153,648.
bluebird bio Inc opened for trading at $51.4 and hit $52.53 on the upside on Monday, eventually ending the session at $51.85, with a gain of 1.21% or 0.62 points. The heightened volatility saw the trading volume jump to 6,94,713 shares. Company has a market cap of $1,927 M.
On the company’s financial health, bluebird bio Inc reported $-1.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.09 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $-1.50. The company had revenue of $1.55 million for the quarter, compared to analysts expectations of $2.01 million. The company’s revenue was down -68.6 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-1.57 EPS.
Many Wall Street Analysts have commented on bluebird bio Inc. Shares were Reiterated by Maxim Group on Aug 4, 2016 to “Buy” and Lowered the Price Target to $ 85 from a previous price target of $105 .bluebird bio Inc was Initiated by Cantor Fitzgerald to “Hold” on Jun 3, 2016.
bluebird bio Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Company’s products include Lenti-D LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy) the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.